Replimune to Present at the Cantor Global Healthcare Conference 2026
Replimune Group, a biotechnology company specializing in oncolytic immunotherapies, announced that its management team will present at the Cantor Global Healthcare Conference on September 10, 2026. The company highlighted its first commercially approved product, TUDRIQEV, for advanced melanoma, and its proprietary RPx platform aiming to enhance can…